A Phase 2 Trial of Zanzalintinib in Advanced/Metastatic Bone Sarcomas (ZAMBONE)

Part of paid clinical trials in Houston, Texas.

Sponsor
M.D. Anderson Cancer Center
Study ID
NCT07193550
Phase
PHASE2
Status
Recruiting
Apply to this trial

Conditions

  • Bone Sarcomas

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Zanzalintinib — DRUG
    Participants will take zanzalintinib 100mg daily by mouth

Study Details

To study the treatment efficacy of zanzalintinib monotherapy in patients with advanced and/or metastatic bone sarcomas.

Key Dates

Start date
Dec 5, 2025
Status verified
Feb 2026
Primary completion
Oct 31, 2029
Completion
Oct 31, 2031

Study Design

Enrollment
70 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Phase 2 Cohorts A, B, C, D: Treatment with Zanzalintinib
    Four cohorts of patients based on biology of the disease will be included in this trial:

Primary Outcome Measure

Safety and Adverse Events (AEs) [ Time Frame: Through study completion; an average of 1 year ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
The University of Texas M. D. Anderson Cancer CenterHoustonTexas77030
John Livingston, MD
[email protected]
713-792-3626
John Livingston, MD (PRINCIPAL_INVESTIGATOR)

Find similar trials in Houston, TX

By research site
The University of Texas M. D. Anderson Cancer Center· Houston, TX

Related Studies